Summary
• SELLAS Life Sciences Group’s stock rose 10.6% to $3.175 following an update on its Phase 3 REGAL trial for galinpepimut-S in acute myeloid leukemia.
• The trial aims to evaluate GPS as maintenance therapy post second complete remission, boosting interest in the company’s cancer treatment development.
• Analysts maintain a “Buy” rating, indicating positive sentiment amidst strong trading volume and significant yearly stock performance.
SELLAS Life Sciences Group, Inc. (SLS) is trading at $3.175, up 10.6% from its previous close, which was not reported. This intraday move follows the company’s recent update on its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), announced earlier today.
REGAL Trial Update Drives Price Action
In a news release dated December 29, 2025, SELLAS provided insights on the ongoing Phase 3 REGAL trial aimed at evaluating GPS as a possible maintenance therapy for patients with AML after achieving a second complete remission (CR2). This trial representation of progress in the treatment of AML comes as the biopharma company is focused on developing novel therapies for various cancer indications. The trial’s potential implications are likely contributing to the stock’s robust performance today.
Market and Trading Performance
Currently, SELLAS exhibits an RSI of 81.75, indicative of potential overbought conditions, while showing a strong monthly performance of 85.2%. The stock has registered a significant weekly uptick of 36.0% as well. Trading volume has spiked with 11,145,371 shares exchanged, well above the average volume of 7,478,151 shares over the past 10 days.
The stock remains well below its 52-week high but has demonstrated a remarkable yearly performance of 219.6%. As it moves, caution is warranted given its high volatility, averaging 10.5% weekly.
Analyst Sentiment
The sentiment surrounding SLS remains positive, with analysts rating it as a “Buy.” This reflects confidence in the company’s trajectory, especially in light of its clinical advancements and strategic focus on cancer therapies.
As shares continue to react to both clinical updates and broader market conditions, investors appear focused on the company’s potential growth, particularly in the oncology sector.